Teva Pharmaceuticals

Teva Pharmaceuticals
Share

Teva Pharmaceuticals

 •  March 6

JERUSALEM--(BUSINESS WIRE)--Mar. 6, 2017-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) will host a live audio webcast at the Cowen & Company 37th Annual Healthcare Conference in Boston, MA. When: Wednesday, March 8, 2017 at 9:20 AM ET Who: Marcelo Bigal, M.D. Ph.D., SVP, Head of Global Specialty Development, Mike Derkacz, SVP, Head...

Teva Pharmaceuticals

 •  February 2

JERUSALEM--(BUSINESS WIRE)--Feb. 2, 2017-- Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) today announced that it has filed an abbreviated new drug application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market the generic version of Novo Nordisk's Victoza® (liraglutide) injection, in the U.S. Victoza® is...

Teva Pharmaceuticals

 •  December 6, 2016

JERUSALEM--(BUSINESS WIRE)--Dec. 6, 2016-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) today announced that it has received a positive outcome through the variation procedure to remove the pregnancy contraindication from the European label for COPAXONE® (glatiramer acetate injection) 20 mg/mL. The product was originally authorized...

Teva Pharmaceuticals

 •  November 16, 2016

Decision solely based on published academic data endorsing the benefit of Trisenox® as first chemotherapy-free treatment for APL and marks important advancement for patients in Europe EU Commission grants an extension of indication to first line use of Trisenox® in combination with retinoic acid APL0406 study revealed a 99% overall survival rate...

Teva Pharmaceuticals

 •  November 15, 2016

Results include the generic business of Actavis, since August 2; Provides updated outlook for 2016. JERUSALEM--(BUSINESS WIRE)--Nov. 15, 2016-- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) today reported results for the quarter ended September 30, 2016. Q3 2016 Revenues $5.6 billion Cash flow from operations $1.5 billion GAAP EPS $0.35 984...

Teva Pharmaceuticals

 •  November 7, 2016

JERUSALEM--(BUSINESS WIRE)--Nov. 7, 2016-- Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) today announced approval of generic Tribenzor®1(olmesartan medoxomil, amlodipine and hydrochlorothiazide) tablets in the U.S. and is in the final stages of launch preparation. Teva also recently received approval and launched generic Azor®2...

Teva Pharmaceuticals

 •  November 2, 2016

Provides Access for Patients and Streamlined Reimbursement JERUSALEM & WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Nov. 2, 2016-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) and Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) announced today that the Centers for Medicare & Medicaid Services (CMS) has established a unique, product-specific...

Teva Pharmaceuticals

 •  October 26, 2016

Programs Include a Systematic Approach to Drug Repurposing & Data-Driven, Proactive Chronic Disease Management -- Both Fueled by the IBM Watson Health Cloud Collaboration Features First Integration of The Weather Company data with IBM Watson Health Cloud LAS VEGAS--(BUSINESS WIRE)--Oct. 26, 2016-- IBM (NYSE:IBM) and Teva Pharmaceutical Industries...

Teva Pharmaceuticals

 •  October 20, 2016

JERUSALEM--(BUSINESS WIRE)--Oct. 20, 2016-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) today announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of the New Drug Application (NDA) for SD-809 (deutetrabenazine) for the treatment of chorea associated with Huntington disease (HD). The FDA has assigned...

Teva Pharmaceuticals

 •  October 17, 2016

JERUSALEM & TARRYTOWN, N.Y.--(BUSINESS WIRE)--Oct. 17, 2016-- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) today provided an update on fasinumab, triggered by a recent development in a Phase 2b fasinumab study in patients with chronic low back pain. Fasinumab is an investigational Nerve...